LDLR and neoplasm: Here, we show that LIPTAC enables efficient, selective, and LDLR-dependent lysosomal degradation of a diverse range of therapeutically relevant membrane proteins, including both single- and multi-pass transmembrane proteins, as well as the cleaved, tumor-specific neoepitopes such as CDCP1.